CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 17 enrolled
Drug / intervention
MK-5720 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05953740
NCT05953740Phase 1Completed
CompareCT.gov

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Long-Acting Injectable of MK-5720 in Participants With Schizophrenia

Merck Sharp & Dohme LLC·interventional·Posted Jul 20, 2023·Updated Mar 4, 2025

In Brief

A Phase 1 clinical trial evaluating MK-5720, Placebo to MK-5720, and 2 other interventions for Schizophrenia. Completed, enrolled 17 participants across 4 sites.

Detailed Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of single ascending intramuscular doses of MK-5720, and the safety and tolerability of multiple once-daily oral doses of MK-8189, in participants with schizophrenia. The primary study hypothesis is that the administration of MK-5720 is safe and well tolerated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
202420252026
First PostedJul 20, 2023
Enrollment StartSep 15, 2023
Primary CompletionFeb 15, 2024
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 2.9 years ago

Interventions

MK-5720drug

IM injection

Placebo to MK-5720drug

Placebo IM Injection matched to MK-5720

MK-8189drug

Oral Tablet

Placebo to MK-8189drug

Placebo oral tablet matched to MK-8189